Loading
A phase 3 trial testing ASC40 in glioma & glioblastoma, active and no longer recruiting.
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM is a phase 3 interventional study registered as NCT05118776, led by Ascletis Pharmaceuticals, and active but no longer recruiting on the registry. Official title: A Phase III Randomised, Double-blind, Placebo-controlled, Multi-centre Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma. Planned enrolment is 136 participants (actual). The study started in 2022-01-21 and primary completion is expected in 2025-06. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/